All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to Hermann Einsele, Julius-Maximilians-Universität Würzburg, Würzburg, DE. We asked, How do you manage bridging therapies prior to CAR T cells in multiple myeloma?
How to manage bridging therapies prior to CAR T cells in multiple myeloma?
Einsele begins by explaining why bridging therapy is important in patients with multiple myeloma with a high tumor load. This is followed by a discussion on what should be considered when choosing a bridging therapy regimen, such as the incidence of cytopenias and infection risk.
Hermann Einsele | EBMT 2019 | CAR T therapy versus targeted antibodies in multiple myeloma
Hermann Einsele | EBMT 2019 | CAR T therapy versus targeted antibodies in multiple myeloma. University Hospital of Würzburg, Würzburg, DE
CAR T Cell Meeting 2019 | CAR T in multiple myeloma: when to use CAR T
On February 14, 2019, Professor Hermann Einsele, University Hospital Würzburg, Germany, presented at the 1st European CAR T Cell Meeting in Paris, France
Subscribe to get the best content related to multiple myeloma delivered to your inbox